Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial is a research paper published in Nature Medicine (2025). On theSindex it has a DataRank of 0.664. It has been cited 40 times, with 30 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.557
From this paper's citation signal
Citation Network Contribution
0.107
From 8 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 30 citers.
NCI NIH HHS
Grant: P30 CA008748
Constellation Pharmaceuticals, a Novartis Company
FWCI
34.30
Citation Percentile
1.0%
Influential Citations
3
Citation Trend
Fields of Study
MeSH Terms
Keywords